Cystatin C and risk of heart failure in the Physicians' Health Study (PHS)

American Heart Journal

Volumn 155, Issue 1, 2008, Pages 82-86

  Djoussé, Luc ^a   Kurth, Tobias ^a   Gaziano, J Michael ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTATIN C;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; HEART FAILURE; HUMAN; HYPERTENSION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; NEPHELOMETRY; PHYSICIAN; PRIORITY JOURNAL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CYSTATINS; FEMALE; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; HYPERTENSION; INCIDENCE; KIDNEY FUNCTION TESTS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHYSICIANS; PILOT PROJECTS; PROBABILITY; PROGNOSIS; PROSPECTIVE STUDIES; REFERENCE VALUES; RISK ASSESSMENT; SEX DISTRIBUTION;

EID: 36849052536     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.08.023     Document Type: Article

References (31)

1. Gottdiener J.S., Arnold A.M., Aurigemma G.P., et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol 35 (2000) 1628-1637
2. Chae C.U., Albert C.M., Glynn R.J., et al. Mild renal insufficiency and risk of congestive heart failure in men and women > or = 70 years of age. Am J Cardiol 92 (2003) 682-686
3. Bibbins-Domingo K., Lin F., Vittinghoff E., et al. Predictors of heart failure among women with coronary disease. Circulation 110 (2004) 1424-1430
4. Sarnak M.J., Katz R., Stehman-Breen C.O., et al. Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med 142 (2005) 497-505
5. Shlipak M.G., Katz R., Sarnak M.J., et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 145 (2006) 237-246
6. Bokenkamp A., Domanetzki M., Zinck R., et al. Cystatin C-a new marker of glomerular filtration rate in children independent of age and height. Pediatrics 101 (1998) 875-881
7. Newman D.J., Thakkar H., Edwards R.G., et al. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int 47 (1995) 312-318
8. Fliser D., and Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis 37 (2001) 79-83
9. Keevil B.G., Kilpatrick E.S., Nichols S.P., et al. Biological variation of cystatin C: implications for the assessment of glomerular filtration rate. Clin Chem 44 (1998) 1535-1539
10. Randers E., and Erlandsen E.J. Serum cystatin C as an endogenous marker of the renal function-a review. Clin Chem Lab Med 37 (1999) 389-395
11. Coll E., Botey A., Alvarez L., et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis 36 (2000) 29-34
12. Peralta C.A., Whooley M.A., Ix J.H., et al. Kidney function and systolic blood pressure new insights from cystatin C: data from the Heart and Soul Study. Am J Hypertens 19 (2006) 939-946
13. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 321 (1989) 129-135
14. Christen W.G., Gaziano J.M., and Hennekens C.H. Design of Physicians' Health Study II-a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials. Ann Epidemiol 10 (2000) 125-134
15. Rexrode K.M., Buring J.E., Glynn R.J., et al. Analgesic use and renal function in men. JAMA 286 (2001) 315-321
16. Wasen E., Isoaho R., Mattila K., et al. Estimation of glomerular filtration rate in the elderly: a comparison of creatinine-based formulae with serum cystatin C. J Intern Med 256 (2004) 70-78
17. Watanabe S., Okura T., Liu J., et al. Serum cystatin C level is a marker of end-organ damage in patients with essential hypertension. Hypertens Res 26 (2003) 895-899
18. Bibbins-Domingo K., Chertow G.M., Fried L.F., et al. Renal function and heart failure risk in older black and white individuals: the Health, Aging, and Body Composition Study. Arch Intern Med 166 (2006) 1396-1402
19. Ho K.K., Anderson K.M., Kannel W.B., et al. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 88 (1993) 107-115
20. Djousse L., and Gaziano J.M. Alcohol consumption and risk of heart failure in the Physicians' Health Study I. Circulation 115 (2007) 34-39
21. Ix J.H., Shlipak M.G., Chertow G.M., et al. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 115 (2007) 173-179
22. Kannel W.B., and Cupples A.C. Epidemiology and risk profiles of cardiac failure. Cardiovasc Drugs Ther 2 (1988) 387-395
23. Lloyd-Jones D.M. The risk of congestive heart failure: sobering lessons from the Framingham Heart Study. Curr Cardiol Rep 3 (2001) 184-190
24. Kannel W.B. Incidence and epidemiology of heart failure. Heart Fail Rev 5 (2000) 167-173
25. Ix J.H., Shlipak M.G., Chertow G.M., et al. Cystatin C, left ventricular hypertrophy, and diastolic dysfunction: data from the Heart and Soul Study. J Card Fail 12 (2006) 601-607
26. Mitsnefes M., Kimbal T., Kartal J., et al. Serum cystatin C and left ventricular diastolic dysfunction in children with chronic kidney disease. Pediatr Nephrol 21 (2006) 1293-1298
27. Abrahamson M., Alvarez-Fernandez M., and Nathanson C.M. Cystatins. Biochem Soc Symp (2003) 179-199
28. Liu J., Sukhova G.K., Sun J.S., et al. Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol 24 (2004) 1359-1366
29. Chapman H.A., Riese R.J., and Shi G.P. Emerging roles for cysteine proteases in human biology. Annu Rev Physiol 59 (1997) 63-88
30. Bengtsson E., To F., Hakansson K., et al. Lack of the cysteine protease inhibitor cystatin C promotes atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 25 (2005) 2151-2156
31. Bengtsson E., To F., Grubb A., et al. Absence of the protease inhibitor cystatin C in inflammatory cells results in larger plaque area in plaque regression of apoE-deficient mice. Atherosclerosis 180 (2005) 45-53